Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) EBIT (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of EBIT data on record, last reported at -$7.3 million in Q3 2025.

  • For Q3 2025, EBIT rose 38.49% year-over-year to -$7.3 million; the TTM value through Sep 2025 reached -$44.7 million, up 13.63%, while the annual FY2024 figure was -$53.3 million, 19.34% up from the prior year.
  • EBIT reached -$7.3 million in Q3 2025 per RANI's latest filing, up from -$10.5 million in the prior quarter.
  • Across five years, EBIT topped out at -$5.2 million in Q1 2021 and bottomed at -$27.8 million in Q3 2021.
  • Average EBIT over 5 years is -$13.9 million, with a median of -$13.8 million recorded in 2022.
  • Peak YoY movement for EBIT: crashed 882.7% in 2021, then skyrocketed 41.18% in 2022.
  • A 5-year view of EBIT shows it stood at -$13.4 million in 2021, then tumbled by 30.83% to -$17.5 million in 2022, then grew by 23.16% to -$13.4 million in 2023, then decreased by 11.34% to -$15.0 million in 2024, then soared by 51.48% to -$7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$7.3 million in Q3 2025, -$10.5 million in Q2 2025, and -$12.0 million in Q1 2025.